Background {#Sec1}
==========

Obesity is an increasing global health concern, with more than 1.9 billion adults worldwide being overweight \[[@CR1]\] and approximately one in two US women of childbearing age now being considered overweight or obese \[[@CR2]\]. Considerable evidence exists showing serious perinatal complications associated with obesity in pregnancy including gestational diabetes (GDM), pre-eclampsia (PE) and neonatal death \[[@CR3]\]. There is also an increased risk of complications such as fetal growth restriction and preterm birth amongst underweight women \[[@CR4]\]. However, evidence is sparse about the effect of interpregnancy weight change on the risk of adverse outcomes in subsequent pregnancies. Current NICE guidelines in the UK recommend that overweight or obese women are referred for weight loss support at the 6--8 week postnatal check-up \[[@CR5]\] despite limited evidence to support widespread implementation of such health promotion strategies and of benefit for future pregnancy outcomes \[[@CR6]\].

The current study aimed to systematically synthesise the published evidence on the associations between interpregnancy weight change and common perinatal complications for both mother and child including GDM, PE, pregnancy induced hypertension (PIH), preterm birth (PTB), and delivery of a large- and small-for-gestational age neonate (LGA and SGA). Additionally, we compared the risk of these complications after interpregnancy weight change in women with a normal BMI and overweight or obese women, and where possible, we investigated the dose-response relationships.

Methods {#Sec2}
=======

Eligibility criteria, information sources, search strategy {#Sec3}
----------------------------------------------------------

The electronic databases PubMed, Ovid EMBASE, [ClinicalTrials.gov](http://clinicaltrials.gov) and Cochrane Central were systematically searched until July 24th, 2019. The search strategy included terms relating to 'interpregnancy', 'between pregnancy', 'weight change' or 'BMI'. These search terms were combined with the outcomes of interest ('gestational diabetes', 'pre-eclampsia', 'pregnancy-induced hypertension', 'preterm birth', 'small-for-gestational age' and 'large-for-gestational age') and synonyms of these outcomes (for full search string see Additional file [3](#MOESM3){ref-type="media"}: Table S1). Furthermore, we cross-referenced selected papers for additional articles to include. The studies identified were uploaded onto Covidence, an online tool for screening of papers for systematic reviews ([www.covidence.org](http://www.covidence.org)). The review protocol was designed a priori and registered with PROSPERO under registration number CRD42017067326.

Study selection {#Sec4}
---------------

Studies were selected using the following predetermined inclusion criteria: \[i\] interpregnancy weight change reported in kilogram (kg), BMI units (kg/m^2^) or percentage body weight change in multiparous women with any time interval between the consecutive births, \[ii\] any of the perinatal outcomes of interest in the subsequent pregnancy, and \[iii\] observational, cohort or case-controlled human study design with a sample size ≥50, that were reported in English. When studies reported data from overlapping study populations, the study with the largest sample size was selected for inclusion. Information extracted from each study included country of research, study cohort name (if applicable), study period, sample size, study inclusion criteria, methods of weight reporting, definition of reference group, diagnostic criteria for perinatal outcomes and demographics that studies adjusted for. All study selection, full text screening, and data extraction was undertaken independently by two researchers (NEWDT and KLM), following PRISMA guidelines \[[@CR7]\]. Disagreements were decided through a third opinion (AMW).

Data synthesis {#Sec5}
--------------

Interpregnancy weight change was defined as the difference between pre-pregnancy weight in the index pregnancy, defined as the earliest recorded pregnancy, and pre-pregnancy weight in the subsequent pregnancy. Interpregnancy weight gain and loss were defined on two categorical scales; (i) for the meta-analysis we utilised categories of \> 1 BMI unit interpregnancy weight loss, BMI gain between 1 and 2 units, BMI gain between 2 and 3 units or BMI gain of more than 3 units and (ii) for the dose-response analysis we utilised a BMI change of 0, 1, 2 or 3+ units. Crude odds ratios (calculated from studies providing relevant counts) and adjusted odds ratios for each outcome of interest were extracted from the selected publications.

Random effects meta-analysis was used to synthesize the odds ratios for weight change categories. To ensure a consistent reference group, only studies that employed a reference group of interpregnancy weight change between 1-unit weight loss and 1-unit weight gain were included. Heterogeneity was assessed using the I^2^ statistic.

We conducted a separate analysis comparing interpregnancy weight change and the risk of developing adverse perinatal outcomes in women with a normal BMI (\< 25 kg/m^2^) versus women with an overweight BMI (≥25 kg/m2), at the start of their index pregnancy. To do so, adjusted odds ratios for both BMI categories were extracted from the publications and summarised by random effects meta-analysis.

Dose-response relationships were assessed by plotting association measurements from studies providing multiple weight gain categories. Where ranges of BMI changes were reported, the midpoint of the category was used (e.g. 1.5 BMI units change for the category weight change between 1 and 2 BMI units).

Statistical analysis and graphical presentation were performed using the *metafor* package in R for Windows, version 3.4.2.

Assessment of risk of bias {#Sec6}
--------------------------

A sensitivity analysis was undertaken to assess potential impact of bias in individual studies by excluding studies that scored below 5 out of 9 points in the Newcastle-Ottawa Scale (NOS \[[@CR8]\]) quality scoring assessment (Additional file [4](#MOESM4){ref-type="media"}: Table S2). Furthermore, leave-one-study-out analyses were conducted to identify whether one study leveraged the overall effect size estimate.

Results {#Sec7}
=======

Study selection {#Sec8}
---------------

We identified and screened 4500 unique publications and included 194 articles for full text review (Fig. [1](#Fig1){ref-type="fig"}). A total of 27 studies were eligible for inclusion. Three studies were excluded due to overlapping study populations \[[@CR9]--[@CR11]\] and one was excluded because of a sample size \< 50 women \[[@CR12]\]. From the remaining 23 studies selected to take forward, a total of 671,906 women were identified for inclusion in the review (Table [1](#Tab1){ref-type="table"}). Eighteen studies included only nulliparous women at the index pregnancy. The proportion of women older than 35 years varied between studies from 3 to 33%. All studies were conducted in Western populations, although this was not an inclusion criterion. Seven studies, comprising of 280,672 women, were included in the meta-analysis. Fig. 1Flow diagram of study inclusion and exclusion Table 1Characteristics of studies investigating the association between interpregnancy weight change and adverse perinatal outcomesAuthor & publication dateIncluded in meta-analysis?^a^CountryStudy cohort (if applicable)Study periodSample sizeInclusion criteriaReported weightReference groupDiagnostic criteriaConfounders adjusted forBogaerts et al. 2013 \[[@CR25]\]YesBelgiumStudy Centre for Perinatal Epidemiology database2009--20117897First two consecutive birthsSelf-reported weight and height±1 BMI unitGDM: not clarifiedPIH: not clarifiedPrepregnancy BMI at first pregnancy, interpregnancy interval, gestational age at first delivery, maternal age, gestational weight gain, complications at first pregnancy (GDM, PIH, induction of labour, CS, malformations and mortality)Bender et al. 2018 \[[@CR46]\]NoUSAHospital of Pennsylvania retrospective cohort2005--2010537Singleton livebirth followed by consecutive pregnancyWeight measured at first antenatal visit, self-reported heightStable BMI categoryGDM: Carpenter--Coustan criteria for the 3-h glucose tolerance testPIH: Task Force on Hypertension in PregnancyPTB: \< 37 weeksMaternal age, GDM in prior pregnancy, prepregnancy BMI categoryBenjamin et al. 2019 \[[@CR39]\]NoUSATexas linked siblings pair2005--20122481Birth certificates linked with older live birth, singleton siblingSelf-reported weight and height0 to \< 1 BMI units weight gainSGA: Not reportedLGA: Not reportedPTB: Not reportedPrepregnancy BMI at sibling pregnancy, ethnicity, smoking status, gestational weight gain, height, maternal age and educationChen et al. 2009 \[[@CR26]\]NoUSACollaborative Perinatal Project1959--19661892Singleton livebirth followed by consecutive singleton pregnancySelf-reported weight and height− 0.32 to 1.48 BMI unitsPTB: \< 37 weeksMaternal age, research centre, race, smoking status, socio-economic index, marital status and interpregnancy intervalCheng et al. 2003 \[[@CR27]\]NoUSAMissouri maternally linked cohort1989--199714,114Second-born SGA infantsSelf-reported weight and heightNo change in BMISGA: \<10th percentileNot reportedCrosby et al. 2017 \[[@CR47]\]NoIrelandFollow up of ROLO study2007--2015280Secundigravida who previously gave birth to macrosomic (\> 4.0 kg) babyWeight and height measured at first antenatal visitNo interpregnancy weight gain (not further specified)GDM: Not specifiedNo adjusted model availableEhrlich et al. 2011 \[[@CR24]\]YesUSAKaiser Permanente Northern California1996--200622,351Women without recognised diabetes before pregnancy, first and second live born singletonsMeasured by clinician at time of alpha fetoprotein test (mean GA 16.9 weeks)± 1.0 BMI unitGDM: According ADA criteriaMaternal age, race, ethnicity, place of birth, GDM status in first pregnancy, prepregnancy BMI in first pregnancy, gestational age, interpregnancy intervalGetahun et al. 2007 \[[@CR28]\]NoUSAMissouri vital record system1989--1997136,884No history of pre-eclampsia in index pregnancy, delivering second baby.Self-reported weight and heightNormal BMI (18.5--24.9 kg/m^2^) in both pregnanciesPE: hypertension and proteinuria beyond 20th week gestation in women normotensive before pregnancyMaternal age, race, education, marital status, prenatal care, smoking status and interpregnancy intervalGetahun et al. 2007 \[[@CR29]\]NoUSAMissouri vital record system1989--1997146,227First two consecutive singleton pregnanciesSelf-reported weight and heightNormal BMI (18.5--24.9 kg/m^2^) in both pregnanciesLGA: ≥90th percentileMaternal age, race, education, marital status, prenatal care, smoking status, alcohol during pregnancy, marital status and interpregnancy intervalGlazer et al. 2004 \[[@CR36]\]NoUSAWashington State Longitudinal Births Database1992--19984102Non-diabetic women with weight ≥ 200lbs. with ≥2 singleton births.Pre-pregnancy weight from birth certificate, unspecified how measured± 10 lbGDM: not clarifiedMaternal age, gestational weight gain in index pregnancy and gestational weight gain during subsequent pregnancyHoff et al. 2009 \[[@CR30]\]NoUSAMissouri birth certificates1995--20041035First two consecutive singleton pregnancies in overweight womenPre-pregnancy weight from birth certificate, unspecified how measuredoverweight BMI (25.0--29.9 kg/m^2^) in both pregnanciesPIH: not clarifiedPTB: \< 37 weeksNo adjusted model availableJain et al. 2013 \[[@CR31]\]NoUSAMissouri vital record system1998--200510,444First two consecutive singleton pregnancies with a BMI ≥ 30 at index pregnancy.Self-reported weight and height± 2 BMI unitsSGA: \<10th percentileLGA:\< 90th percentileMaternal ae, race, martial status, education, socioeconomic status, obesity status in first pregnancy, gestational weight gain, smoking, PE, prenatal care, previous SGA or LGA birth, DM, hypertension, renal or cardiac diseaseKnight-Agarwal et al. 2016 \[[@CR32]\]YesAustraliaBirthing Outcome System2008--201314,875Women of all parity with subsequent pregnancies.Weight and height recorded at first antenatal visit (mean GA not reported)± 1 BMI unitGDM: not clarifiedMaternal age, parity, country of birth, smoking statusKruse et al. 2015 \[[@CR33]\]NoDenmark--2009--201372Primiparas with a history of GDMUnspecified how weight was recordedNo change in BMI unitsGDM: ≥9.0 mmol/L blood glucose 2 h after OGTT.No adjusted model availableLynes et al. 2017 \[[@CR22]\]YesUSANICHD Consecutive Pregnancy Study2002--201046,521First two consecutive singleton birthsUnspecified how weight was recorded± 1 BMI unitGDM: not clarifiedPIH: ≥140 mmHg systolic and ≥ 90 mmHg diastolic without proteinuriaPE: ≥140 mmHg systolic and ≥ 90 mmHg diastolic with proteinuriaMaternal race, interpregnancy interval, maternal age, marital status, smoking status, alcohol use during second pregnancy, prepregnancy BMI, complication in first pregnancy (GDM, PE, PIH)McBain et al. 2016 \[[@CR34]\]NoAustraliaWomen's and Childeren's Health Network2000--20125371First and second consecutive deliveries.BMI units recorded at first antenatal visit (before GA 15 weeks)±2 BMI unitsGDM: not clarifiedPTB: not clarifiedSGA: \<10th centileLGA: ≥90th centileMaternal age, socioeconomic status, prepregnancy BMI in first pregnancy, smoking status, race, interpregnancy interval, first pregnancy outcome (GDM, PIH, birth method, LGA and SGA)Pole et al. 1999 \[[@CR37]\]NoCanadaNova Scotia Atlee Perinatal Database1988--199619,932Two or more singletonsNot stated± 3% weightGDM: two abnormal glucose values on a GTT according to Joslin Clinic or O'Sullivan criteria.PIH: BP ≥90 mmHg diastolic, twice in 24 hPrepregnancy weight (in lbs) of index pregnancy, gestational age, marital status, previous CS, maternal age, gestational weight gain, GDM in previous pregnancySimonsen et al. 2013 \[[@CR38]\]NoUSAMaternally linked Utah birth and fetal records1989--20078468First three singletonlive births.Pre-pregnancy BMI from birth certificate (mean GA not reported)BMI category unchangedPTB: ≥20 and \< 37 weeksMaternal age, ethnicity, gestational weight gain, father on birth record, interpregnancy interval, subtype of previous PTB, gestational age at previous PTB, fetal death or anomaly in historySorbye et al. 2017 \[[@CR23]\]YesNorwayMedical Birth Registry of Norway2006--201424,198First and second delivery without GDM in index pregnancyUnspecified how weight was recorded± 1 BMI unitsGDM: fasting glucose \< 7.0 mmol/l and serum glucose after OGTT ≥7.8 mmol/lMaternal age, country of birth, maternal education, smoking status, interpregnancy interval and year of deliveryVillamor et al. 2006 \[[@CR20]\]YesSwedenSwedish Birth Register1992--2001151,025First and second consecutive singleton births.BMI units recorded at first antenatal visit (mean GA not reported)± 1 BMI unitsGDM: ICD-9648 W, ICD-10 O244.PE: ICD-9642E-642H, ICD-10 O11 and O14.PIH: ICD-9642D and 642X, ICD-10 O13LGA: ≥2 SD above mean birthweightPrepregnancy BMI in first pregnancy, height, interpregnancy interval, maternal age, country of birth, education, year of delivery, smoking statusWallace et al. 2014 \[[@CR21]\]YesScotlandAberdeen Maternity and Neonatal Databank1986--200712,740First two consecutive births.Weight and height recorded at first antenatal visit (mean GA not reported)± 1 BMI unitsPE: ISSHP definitionPIH: ISSHP definitionPTB: \< 37 weeksSGA: \<10th percentileLGA: ≥90th percentilePrepregnancy BMI in first pregnancy, height inter-delivery interval, maternal age, year of delivery, smoking status, gestational age and fetal gender at second pregnancy.Wallace et al. 216 \[[@CR35]\]NoScotlandAberdeen Maternity and Neonatal Databank1986--201324,520First two consecutive births and the same perinatal complication in both pregnanciesWeight and height recorded at first antenatal visit (mean GA not reported)± 2 BMI unitsPTB: \< 37 weeksPE: ISSHP definitionPIH: ISSHP definitionSGA: \<10th percentileLGA: ≥90th percentilePrepregnancy BMI in first pregnancy, year of delivery, height, inter-delivery interval, maternal age, smoking status, gestational age and fetal sex at first and second pregnancyZiauddeen et al. 2019 \[[@CR19]\]YesEnglandBirth registry at Southampton Hospital2003--201715,940First two consecutive singleton live-birth pregnanciesWeight recorded at first antenatal visit; height self-reported± 1 BMI unitLGA: \>90th percentile for GABaseline BMI, maternal age, education level, infertility treatment, smoking status, employment status, GDM in current pregnancy and interpregnancy interval^a^To ensure a consistent reference group, only studies that employed a reference group of interpregnancy weight change between 1-unit weight loss and 1-unit weight gain were included. *GDM* gestational diabetes, *PE* pre-eclampsia, *PIH* pregnancy induced hypertension, *PTB* preterm birth, *SGA* small-for-gestational age, *LGA* large-for gestational age, *BMI* body mass index, *GA* gestational age, *CS* caesarean section, *DM* diabetes mellitus

Synthesis of results {#Sec9}
--------------------

Interpregnancy weight gain of between 1 and 2 BMI units was associated with a 51% higher risk of developing GDM (aOR 1.51 \[1.22--1.80\], I^2^ = 70.1%), whereas an increase of 2--3 or more than 3 BMI units was associated with an 81 and 137% higher risk (aOR 1.81 \[1.20--2.41\], I^2^ = 88.4% and aOR 2.37 \[1.50--3.34\], I^2^ = 91.0% respectively) (Fig. [2](#Fig2){ref-type="fig"}). Furthermore, interpregnancy weight gain of more than 3 BMI units was associated with a higher risk of PE or PIH (aOR 1.70 \[1.50--1.91\], I^2^ = 0.0% and aOR 1.71 \[1.51--1.91\] I^2^ = 0.0% respectively) (Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). The association between interpregnancy weight change and the risk of delivering an LGA neonate could only be estimated for a weight gain \> 3 BMI units, and showed a 63% higher risk (aOR 1.63 \[1.30--1.97\], I^2^ = 85.6%) (Fig. [5](#Fig5){ref-type="fig"}). In contrast, interpregnancy weight loss of \> 1 BMI unit was associated with a lower risk of delivering an LGA neonate, (aOR 0.79 \[0.58--0.99\], I^2^ = 86.1%) (Fig. [5](#Fig5){ref-type="fig"}), but there was no conclusive evidence of association of interpregnancy weight loss with the risk of developing GDM, PE or PIH (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}). There was an insufficient number of studies to conduct a meta-analysis on adjusted odds ratios for the outcomes of SGA and PTB. A meta-analysis combining the crude odds ratios rather than adjusted ratios showed a significant higher risk of developing PE (cOR 1.31 \[1.09--1.53\], I^2^ = 75.1%), but showed similar results for the association between interpregnancy weight gain and the risk of developing GDM, PE or PIH (Additional file [1](#MOESM1){ref-type="media"}: Figure S1 for interpregnancy weight loss and Additional file [2](#MOESM2){ref-type="media"}: Figure S2 for weight gain). For the outcomes of SGA and PTB, meta-analyses of crude odds ratios showed interpregnancy weight loss of \> 1 BMI unit was associated with a higher risk of delivering a SGA neonate or delivering preterm (cOR 1.53 \[1.35--1.71\], I^2^ = 0.0% and cOR 1.45 \[1.21--1.69\], I^2^ = 26.7%\] respectively), but there was no evidence of association with interpregnancy weight gain (Additional file [1](#MOESM1){ref-type="media"}: Figure S1 and Additional file [2](#MOESM2){ref-type="media"}: Figure S2). Fig. 2Forest plot from random effects meta-analysis showing the association between interpregnancy weight change and the risk of developing gestational diabetes in subsequent pregnancy. All adjusted odds ratios are relative to the reference category of interpregnancy weight change between − 1 and + 1 BMI units. BMI, body mass index (in kg/m^2^); aOR, adjusted odds ratio; CI, confidence interval Fig. 3Forest plot from random effects meta-analysis showing the association between interpregnancy weight change and the risk of developing pre-eclampsia in subsequent pregnancy. All adjusted odds ratios are relative to the reference category of interpregnancy weight change between − 1 and + 1 BMI units. BMI, body mass index (in kg/m^2^); aOR, adjusted odds ratio; CI, confidence interval Fig. 4Forest plot from random effects meta-analysis showing the association between interpregnancy weight change and the risk of developing pregnancy induced hypertension in subsequent pregnancy. All adjusted odds ratios are relative to the reference category of interpregnancy weight change between − 1 and + 1 BMI units. BMI, body mass index (in kg/m^2^); aOR, adjusted odds ratio; CI, confidence interval Fig. 5Forest plot from random effects meta-analysis showing the association between interpregnancy weight change and the risk of delivering a large-for-gestational age neonate in subsequent pregnancy. All adjusted odds ratios are relative to the reference category of interpregnancy weight change between − 1 and + 1 BMI units. BMI, body mass index (in kg/m^2^); aOR, adjusted odds ratio; CI, confidence interval

Figures [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"} and [8](#Fig8){ref-type="fig"} show the odds ratios for the risk of developing an adverse perinatal outcome after interpregnancy weight gain, stratified by BMI category in the index pregnancy (normal weight; BMI \< 25 kg/m^2^ versus overweight; BMI ≥25 kg/m^2^). Women with a normal weight at the start of the index pregnancy had a higher risk of developing GDM after interpregnancy weight gain \> 3 BMI units (aOR 4.36 \[2.29--6.44\], I^2^ = 81.6%) compared to women with an overweight BMI (aOR 2.26 \[1.40--3.12\], I^2^ = 74.4%) (Fig. [6](#Fig6){ref-type="fig"}a and b). Similarly, women with a BMI \< 25 kg/m^2^ were at higher risk of delivering a LGA neonate after interpregnancy weight gain \> 3 BMI units than women with BMI ≥25 kg/m^2^ (aOR 1.80 \[1.24--2.35\], I^2^ = 87.2% versus aOR 1.50 \[1.35--1.66\], I^2^ = 0.0% respectively) (Fig. [7](#Fig7){ref-type="fig"}a and b). Women with a normal BMI at the start of their index pregnancy were at higher risk of developing PIH in a subsequent pregnancy after interpregnancy weight gain of 2--3 BMI (aOR 1.60 \[1.04--2.16, I^2^ = 54.6%) and \> 3 BMI units (aOR 2.21 \[1.81--2.60\], I^2^ = 0.0%), compared to women with an overweight BMI (2--3 units gain; aOR 0.95 \[0.73--1.17\], I^2^ = 0.0%, \> 3 units gain; aOR 1.37 \[1.16--1.59\], I^2^ = 0.0%) (Fig. [8](#Fig8){ref-type="fig"}a and b). We did not find differential effects of interpregnancy weight loss between women with a normal BMI and women with an overweight BMI on the risk of developing GDM, PIH or delivering an LGA neonate. Fig. 6Forest plot from random effects meta-analysis showing association between interpregnancy weight change and the risk of developing gestational diabetes, stratified by BMI category at the start of index pregnancy. **a** Normal weight classified as BMI \< 25 kg/m^2^; **b** Overweight classified as BMI ≥25 kg/m^2^. All adjusted odds ratios are relative to the reference category of interpregnancy weight change between − 1 and + 1 BMI units. BMI, body mass index (in kg/m^2^); aOR, adjusted odds ratio; CI, confidence interval Fig. 7Forest plot from random effects meta-analysis showing association between interpregnancy weight change and the risk of delivering a large-for-gestational age neonate, stratified by BMI category at the start of index pregnancy. **a** Normal weight classified as BMI \< 25 kg/m^2^; **b** Overweight classified as BMI ≥25 kg/m^2^. All adjusted odds ratios are relative to the reference category of interpregnancy weight change between − 1 and + 1 BMI units. BMI, body mass index (in kg/m^2^); aOR, adjusted odds ratio; CI, confidence interval Fig. 8Forest plot from random effects meta-analysis showing association between interpregnancy weight change and the risk of developing pregnancy induced hypertension, stratified by BMI category at the start of index pregnancy. **a** Normal weight classified as BMI \< 25 kg/m^2^; **b** Overweight classified as BMI ≥25 kg/m^2^. All adjusted odds ratios are relative to the reference category of interpregnancy weight change between − 1 and + 1 BMI units. BMI, body mass index (in kg/m^2^); aOR, adjusted odds ratio; CI, confidence interval

There was an approximate log-linear association between interpregnancy weight gain and the risk of developing GDM (Fig. [9](#Fig9){ref-type="fig"}a), PE (Fig. [9](#Fig9){ref-type="fig"}b) or PIH (Fig. [9](#Fig9){ref-type="fig"}c) and delivering a LGA neonate (Fig. [9](#Fig9){ref-type="fig"}d). Fig. 9Dose-response curve with line of best fit for the increase in odds ratio of developing perinatal complications after interpregnancy weight gain. **a** Gestational Diabetes. **b** Pre-eclampsia. **c** Pregnancy Induced Hypertension **d** Large-for-gestational age. Where ranges of BMI changes were reported, the midpoint category was utilised (e.g. 1.5 BMI units change for the category weight change between 1 and 2 BMI units). aOR, adjusted odds ratio. BMI, body mass index (in kg/m^2^)

Risk of bias of included studies {#Sec10}
--------------------------------

After assessing the study selection criteria, comparability of cases and controls and outcome assessments through the NOS, we identified four studies of poor quality (NOS score \< 5, Additional file [4](#MOESM4){ref-type="media"}: Table S2). However, as these studies did not employ a reference group of ±1 BMI unit, they were already excluded from the meta-analyses. Leave-one-out-analyses showed that removing the study by Villamor et al. made the association between GDM and interpregnancy weight change of 2--3 or \> 3 BMI units not significant. We did not find evidence that the outcomes for PE or PIH were driven by one study. For the outcome of delivering an LGA neonate, leave-one-out analyses could not be conducted due to only two studies being included in the meta-analysis.

Discussion {#Sec11}
==========

Main findings {#Sec12}
-------------

This study systematically summarises and examines the published literature on the associations between interpregnancy weight change and several common perinatal outcomes. Our main findings are that interpregnancy weight gain is associated with a higher risk of developing GDM, PE, PIH and delivering an LGA neonate, while interpregnancy weight loss is associated with a lower risk of delivering an LGA neonate. BMI at the start of the index pregnancy possibly modifies the risk of developing GDM, PIH or delivering an LGA neonate after interpregnancy weight gain. Furthermore, we identify a positive approximately log-linear relationship between interpregnancy weight gain and the risk of developing GDM, PE, PIH or delivering a LGA neonate.

Comparison with existing literature {#Sec13}
-----------------------------------

Our study confirms the associations between interpregnancy weight gain and the risk of developing GDM and LGA, as also shown in a recent meta-analysis \[[@CR13]\]. Our research additionally summarises the effect of interpregnancy weight change on the risk of developing hypertensive disorders in pregnancy. However, our meta-analysis is to the authors knowledge the first study to show that gaining weight between pregnancies increases the risk of developing hypertensive disorders in the subsequent pregnancy. The observation that starting BMI possibly modifies this association is important for women with a healthy BMI at the start of their index pregnancy, as research often emphasises the risk associated with being overweight or obese, and women with a healthy BMI might not be aware of the risk that comes with (small) interpregnancy weight gain. Although the risks of (excessive) gestational weight gain \[[@CR14]\] and high pre-pregnancy BMI \[[@CR15], [@CR16]\] on perinatal outcomes are well understood, the effects of interpregnancy weight gain are relatively unknown and are essential to understand in order to guide women in periconception and perinatal weight management.

Our study shows an approximate log-linear association between BMI gain and the risk of developing GDM or hypertensive disorders in pregnancy. This result contributes towards understanding the association between maternal weight and pregnancy complications. Linear dose-response associations are established between obesity and the incidence of GDM, PE and PIH \[[@CR17]\], between adiposity and pre-eclampsia \[[@CR18]\], as well as maternal weight and pre-eclampsia \[[@CR15]\] and GDM \[[@CR16]\]. Our identified associations emphasise the detrimental effects of (small amounts of) weight gain, additional to the influence of absolute BMI. This can contribute towards understanding the importance of postpartum weight management and highlights the need for the development of clinical guidelines.

Strengths and limitations {#Sec14}
-------------------------

A strength of our study is we ensured a homogenous reference group (i.e. a BMI change ≤1 kg/m^2^) for our meta-analysis rather than including studies with very different reference groups \[[@CR13]\]. Furthermore, we only harmonised studies reporting adjusted odds ratios, which all considered maternal age, country of origin, social economic status and smoking status as potential confounders. Nevertheless, our study has several limitations. First, between-study heterogeneity remained, arising from differences in outcome definitions and demographics, such as parity and age, and potentially differences in length of interpregnancy intervals and prevalence of perinatal complications. Of the studies selected for meta-analysis, only Lynes et al. did not restrict to nulliparous women, although removing this study had little impact on the results. Second, GDM, PE and PIH were either not defined in publications or the definitions of these adverse outcomes differed between studies, hence caution is needed when comparing effect estimates between studies. Third, it was not possible to consistently assess the impact of previous pregnancy complications, which may lead to excessive interpregnancy weight changes and a higher risk of subsequent pregnancy complications. Fourth, studies varied in the way they measured pre-pregnancy weight, with the majority of studies using self-reported weight (and height) to calculate BMI and interpregnancy weight change. Although evidence suggests that maternal reports of pre-pregnancy weight are in general consistent with clinical records \[[@CR42]\], bias due to systematic over- or underreporting cannot be excluded. We can also not exclude the possibility of publication bias, as this could not be assessed due to the small number of studies available per adverse outcome and funnel plot assessment is generally not recommended with less than 10 studies \[[@CR43]\]. Lastly, we were unable to make the distinction between spontaneous preterm birth and medically induced preterm birth. We hypothesise that an increased risk of preterm birth is at least partly related to the increased risk of carrying an SGA neonate, as (suspected) growth restriction is one of the main causes of medically induced premature birth \[[@CR44]\]. However, inadequate nutrition in the context of severe maternal weight loss could also contribute to a higher risk of both SGA and preterm birth \[[@CR45]\].

Conclusions {#Sec15}
===========

Our study highlights the importance of postpartum weight management, but also identifies opportunities for future research. There is a need to capture the typical weight change profiles of women in various BMI classes, to further elucidate risk groups. This will support further research into weight management strategies, eventually aiming to implement evidence-based weight control interventions to benefit maternal and offspring health. It is particularly important to elucidate strategies for postpartum weight loss in normal weight women, as this group might not be the focus of current research and interventions, yet may be at highest risk of adverse outcomes from interpregnancy weight gain.

In conclusion, we show that interpregnancy weight gain impacts on the risk of developing perinatal complications in a subsequent pregnancy and it is possible that BMI at the index pregnancy modifies these associations. These findings highlight the need to encourage women to return to their pre-pregnancy weight before conceiving again in an effort to reduce the risk of perinatal complications. Future work should focus on defining the most effective strategies to achieve this outcome.
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=========================

 {#Sec16}

**Additional file 1: Figure S1.** Forest plot from random effects meta-analysis showing the crude odds ratios for the association between interpregnancy weight loss and the risk for perinatal outcomes of interest. Black, solid dots represent studies with reference group of interpregnancy weight change between − 1 and + 1 BMI unit and are therefore included in the meta-analyses. White, open dots represent studies not using a reference group of interpregnancy weight change between 1-unit weight loss and 1-unit weight gain and are visually displayed but not included in the meta-analysis. cOR, crude odds ratio; CI, confidence interval. **Additional file 2: Figure S2.** Forest plot from random effects meta-analysis showing the crude odds ratios for the association between interpregnancy weight gain and the risk for perinatal outcomes of interest. Black, solid dots represent studies with reference group of interpregnancy weight change between − 1 and + 1 BMI unit and are therefore included in the meta-analyses. White, open dots represent studies not using a reference group of interpregnancy weight change between 1-unit weight loss and 1-unit weight gain and are visually displayed but not included in the meta-analysis. cOR, crude odds ratio; CI, confidence interval. **Additional file 3: Table S1.** Search string. **Additional file 4: Table S2.** Assessment of study quality through the Newcastle--Ottawa scale.
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